Tositumomab and iodine -131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of low-grade or transformed, low-grade non-Hodgkin’s lymphoma (NHL).
T. A. Lister
Advertisement
Articles by T. A. Lister
The chimeric monoclonal anti-CD20 antibody rituximab (Rituxan) has been shown to have clinical activity in patients with
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
2
FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer
3
EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC
4
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
5